Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.

ABSTRACT:

Purpose

To quantify clinical trial participants' and investigators' judgments with respect to the relative importance of efficacy and safety attributes of antipsychotic treatments for schizophrenia, and to assess the impact of formulation and adherence.

Methods

Discrete-choice experiment surveys were completed by patients with schizophrenia and physician investigators participating in two phase-3 clinical trials of paliperidone palmitate 3-month long-acting injectable (LAI) antipsychotic. Respondents were asked to choose between hypothetical antipsychotic profiles defined by efficacy, safety, and mode of administration. Data were analyzed using random-parameters logit and probit models.

Results

Patients (N=214) and physicians (N=438) preferred complete improvement in

SUBMITTER: Katz EG 

PROVIDER: S-EPMC5085312 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature